CEBPA single mutation can be a possible favorable prognostic indicator in NPM1 and FLT3-ITD wild-type acute myeloid leukemia patients with intermediate cytogenetic risk

Leukemia Research

Volumn 37, Issue 11, 2013, Pages 1488-1494

  Park, Sang Hyuk ^a   Chi, Hyun Sook ^a   Cho, Young Uk ^a   Jang, Seongsoo ^a   Park, Chan Jeoung ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Acute myeloid leukemia; CEBPA; Incidence; Prognosis

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA; CD135 ANTIGEN; DNA METHYLTRANSFERASE 3A; ISOCITRATE DEHYDROGENASE 2; NUCLEOPHOSMIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER REGRESSION; CANCER SURVIVAL; CEBPA GENE; CYTOGENETICS; DNMT3A GENE; FEMALE; FLT3 GENE; GENE; GENE MUTATION; GENETIC RISK; HUMAN; IDH2 GENE; MAJOR CLINICAL STUDY; MALE; NMP1 GENE; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; WILD TYPE;

ACUTE MYELOID LEUKEMIA; CEBPA; INCIDENCE; PROGNOSIS;

ADOLESCENT; ADULT; AGED; CCAAT-ENHANCER-BINDING PROTEINS; CHILD; CYTOGENETIC ANALYSIS; FEMALE; FMS-LIKE TYROSINE KINASE 3; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; NUCLEAR PROTEINS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TANDEM REPEAT SEQUENCES; YOUNG ADULT;

EID: 84886776387     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.08.014     Document Type: Article

References (29)

1. Grimwade D., Walker H., Oliver F., Wheatley K., Harrison C., Harrison G., et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998, 92:2322-2333.
2. Grimwade D., Walker H., Harrison G., Oliver F., Chatters S., Harrison C.J., et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML 11 trial. Blood 2001, 98:1312-1320.
3. Grimwade D., Hills R.K., Moorman A.V., Walker H., Chatters S., Goldstone A.H., et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010, 116:354-365.
4. Schoch C., Haferlach T., Haase D., Fonatsch C., Löffler H., Schlegelberger B., et al. Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients. Br J Haematol 2001, 112:118-126.
5. Grossmann V., Schnittger S., Kohlmann A., Eder C., Roller A., Dicker F., et al. A novel hierarchical prognostic model of AML solely based on molecular mutations. Blood 2012, 120:2963-2972.
6. O'Donnell M.R., Abboud C.N., Altman J., Appelbaum F.R., Arber D.A., Attar E., et al. Acute myeloid leukemia. J Natl Compr Cancer Netw 2012, 10:984-1021.
7. Mueller B.U., Pabst T. C/EBPalpha and the pathophysiology of acute myeloid leukemia. Curr Opin Hematol 2006, 13:7-14.
8. Jost E., do O.N., Wilop S., Herman J.G., Osieka R., Galm O. Aberrant DNA methylation of the transcription factor C/EBPalpha in acute myelogenous leukemia. Leuk Res 2009, 33:443-449.
9. Pabst T., Mueller B.U. Complexity of CEBPA dysregulation in human acute myeloid leukemia. Clin Cancer Res 2009, 15:5303-5307.
10. Benthaus T., Schneider F., Mellert G., Zellmeier E., Schneider S., Kakadia P.M., et al. Rapid and sensitive screening for CEBPA mutations in acute myeloid leukaemia. Br J Haematol 2008, 143:230-239.
11. Marcucci G., Maharry K., Radmacher M.D., Mrozek K., Vukosavljevic T., Paschka P., et al. Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. J Clin Oncol 2008, 26:5078-5087.
12. Renneville A., Boissel N., Gachard N., Naguib D., Bastard C., de Botton S., et al. The favorable impact of CEBPA mutations in patients with acute myeloid leukemia is only observed in the absence of associated cytogenetic abnormalities and FLT3 internal duplication. Blood 2009, 113:5090-5093.
13. Wouters B.J., Lowenberg B., Erpelinck-Verschueren C.A., van Putten W.L., Valk P.J., Delwel R. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood 2009, 113:3088-3091.
14. Ho P.A., Alonzo T.A., Gerbing R.B., Pollard J., Stirewalt D.L., Hurwitz C., et al. Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. Blood 2009, 113:6558-6566.
15. Abbas S., Lugthart S., Kavelaars F.G., Schelen A., Koenders J.E., Zeilemaker A., et al. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. Blood 2010, 116:2122-2126.
16. Paschka P., Schlenk R.F., Gaidzik V.I., Habdank M., Kronke J., Bullinger L., et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 2010, 28:3636-3643.
17. Chao H.Y., Jia Z.X., Chen T., Lu X.Z., Cen L., Xiao R., et al. IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia and associated with NPM1 mutations and FAB-M2 subtype. Int J Lab Hematol 2012, 34:502-509.
18. Ravandi F., Patel K., Luthra R., Faderl S., Konopleva M., Kadia T., et al. Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin. Cancer 2012, 118:2665-2673.
19. Ley T.J., Ding L., Walter M.J., McLellan M.D., Lamprecht T., Larson D.E., et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010, 363:2424-2433.
20. Markova J., Michkova P., Burckova K., Brezinova J., Michalova K., Dohnalova A., et al. Prognostic impact of DNMT3A mutations in patients with intermediate cytogenetic risk profile acute myeloid leukemia. Eur J Haematol 2012, 88:128-135.
21. Taskesen E., Bullinger L., Corbacioglu A., Sanders M.A., Erpelinck C.A., Wouters B.J., et al. Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. Blood 2011, 117:2469-2475.
22. Dufour A., Schneider F., Hoster E., Benthaus T., Ksienzyk B., Schneider S., et al. Monoallelic CEBPA mutations in normal karyotype acute myeloid leukemia: independent favorable prognostic factor within NPM1 mutated patients. Ann Hematol 2012, 91:1051-1063.
23. WHO classification of tumours of hematopoietic and lymphoid tissues 2008, IARC Press, Lyon. 4th ed. S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein (Eds.).
24. Shen Y., Zhu Y.M., Fan X., Shi J.Y., Wang Q.R., Yan X.J., et al. Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia. Blood 2011, 118:5593-5603.
25. Kim S., Kim D.H., Jang J.H., Jung C.W., Jang M.A., Ki C.S., et al. Novel mutations in CEBPA in Korean Patients with acute myeloid leukemia with a normal karyotype. Ann Lab Med 2012, 32:153-157.
26. Frohling S., Schlenk R.F., Stolze I., Bihlmayr J., Benner A., Kreitmeier S., et al. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol 2004, 22:624-633.
27. Lin L.I., Chen C.Y., Lin D.T., Tsay W., Tang J.L., Yeh Y.C., et al. Characterization of CEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells. Clin Cancer Res 2005, 11:1372-1379.
28. Resende C., Regalo G., Duraes C., Carneiro F., Machado J.C. Genetic changes of CEBPA in cancer: mutations or polymorphisms?. J Clin Oncol 2007, 25:2493-2494. author reply 4-5.
29. Wouters B.J., Louwers I., Valk P.J., Lowenberg B., Delwel R. A recurrent in-frame insertion in a CEBPA transactivation domain is a polymorphism rather than a mutation that does not affect gene expression profiling-based clustering of AML. Blood 2007, 109:389-390.